Moderna Surges 176% on Vaccine Success as Marvell and Google Expand AI Ties

Key Facts

1Moderna shares surged over 176% following positive late-stage trial results for its cancer vaccine with Merck.

2Marvell Technology shares gained on news of an expanding AI partnership with Google involving a $12.2 billion stake.

3Gold jumped 3% as US Treasury bond buybacks pushed yields and the dollar lower.

Reflecting a surge of innovation across the healthcare and technology sectors, US markets witnessed sharp price movements driven by clinical and strategic breakthroughs. Moderna shares skyrocketed by over 176% following positive late-stage trial results for a cancer vaccine developed in partnership with Merck. Simultaneously, Marvell Technology shares gained momentum on news of an expanding AI partnership with Google involving a $12.2 billion stake.

In broader market action, Gold jumped 3% as US Treasury bond buybacks pushed yields and the dollar lower. According to market data, Marvell Technology (MRVL) closed at $216 on August 18, 2026, while Merck (MRK) settled at $135.18 on the same date. Per market data, Google (GOOGL) closed at $344.41 on August 19, 2026, amid a mixed session for tech peers where Microsoft (MSFT) finished at $484.345.

Traders are now watching support levels for MRVL after it hit a session high of $225.01 before closing at $216 (as of August 18, 2026). Looking ahead, while the upcoming economic calendar shows no direct catalysts for these specific firms in the next seven days, the market remains focused on the long-term implications of Moderna's clinical success and the scale of the Marvell-Google AI alliance.

Sources:

invezz.com